688185.SS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 09:00):

Stats
Dagens volum	1.57M
Gjennomsnittsvolum	1.59M
Markedsverdi	6.43B
EPS	CNY0 ( 2024-04-29 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-8.50
ATR14	CNY0.0530 (0.10%)

Volum Korrelasjon

Lang: 0.05 (neutral)

Kort: -0.77 (moderate negative)

Signal:(34.547) Neutral

CanSino Biologics Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

CanSino Biologics Inc. Korrelasjon - Valuta/Råvare

0.63
( weak )

0.24
( neutral )

0.00
( neutral )

0.66
( moderate )

-0.37
( neutral )

0.38
( neutral )

CanSino Biologics Inc. Økonomi

Annual	2023
Omsetning:	CNY349.12M
Bruttogevinst:	CNY-21.83M (-6.25 %)
EPS:	CNY-6.01

FY	2023
Omsetning:	CNY349.12M
Bruttogevinst:	CNY-21.83M (-6.25 %)
EPS:	CNY-6.01

FY	2022
Omsetning:	CNY1.03B
Bruttogevinst:	CNY-186.61M (-18.10 %)
EPS:	CNY-3.91

FY	2021
Omsetning:	CNY4.30B
Bruttogevinst:	CNY3.00B (69.85 %)
EPS:	CNY7.74

Financial Reports:

No articles found.

CanSino Biologics Inc.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.